Our biomarker-driven approach will
redefine cancer treatment.
- Company
- Therapeutic Areas
- Programs
- Clinical Trials
- Investors
- Financial Information
- Corporate Governance
- Shareholder Services
-
Calithera to Present at the 2021 Jefferies London Healthcare Conference
-
Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
-
Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer
-
Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
-
Calithera Biosciences to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
Development Pipeline
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Recent News
- Shareholder Services
- Corporate Governance
- Financial Information
- Investors
- Clinical Trials
- Programs
- Therapeutic Areas
